AbbVie
ABBV
$191.08
Share price
-0.70%
Change (1 day)
12.61%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
AbbVie (ABBV) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : $134.70 Billion USD
According to AbbVie's latest financial reports the company's total liabilities are $134.70 Billion USD. A company’s total liabilities is the sum of all current and non-current debts and obligations.
AbbVie - Total liabilities on balance sheet (from 2011 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | $131.79 B | 6.02% |
| 2023-12-31 | $124.31 B | 2.3% |
| 2022-12-31 | $121.51 B | -7.3% |
| 2021-12-31 | $131.09 B | -4.64% |
| 2020-12-31 | $137.46 B | 41.3% |
| 2019-12-31 | $97.28 B | 43.5% |
| 2018-12-31 | $67.79 B | 3.21% |
| 2017-12-31 | $65.68 B | 6.88% |
| 2016-12-31 | $61.46 B | 25.17% |
| 2015-12-31 | $49.10 B | 90.54% |
| 2014-12-31 | $25.77 B | 4.31% |
| 2013-12-31 | $24.70 B | 4.49% |
| 2012-12-31 | $23.64 B | 211.57% |
| 2011-12-31 | $7.58 B | 39.72% |
| 2010-12-31 | $5.43 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $117.39 B | -12.85% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $74.97 B | -44.34% | 🇺🇸 USA |
 Eli Lilly LLY | $73.54 B | -45.40% | 🇺🇸 USA |
 Amgen AMGN | $83.16 B | -38.26% | 🇺🇸 USA |
 Gilead Sciences GILD | $37.35 B | -72.27% | 🇺🇸 USA |
 Biogen BIIB | $11.05 B | -91.79% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $60.87 B | -54.81% | 🇬🇧 UK |
 AstraZeneca AZN | $65.12 B | -51.66% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | $1.15 B | -99.14% | 🇺🇸 USA |